Brief introduction of cefdizime

Cefodizime is a product originally developed by HOECHST, Germany, with the trade name of Mody. When the European and American patents expired in 2002, Xinglin Pharmaceutical was approved to be listed in Japan, Recordati Company was listed in Italy and Medac Company was listed in Germany. Cefodizime is a semi-synthetic third-generation cephalosporin broad-spectrum antibacterial agent, which has antibacterial activity against both Gram-positive and Gram-negative bacteria, is stable to β -lactamase and extremely stable to cephalosporinase and Penicillinase. Clinically, it is mainly used for pneumonia, bronchitis, pharyngolaryngitis, tonsillitis, pyelonephritis, urinary tract infection, gonococcal urethritis, cholecystitis, cholangitis, gynecological infection, septicemia, otitis media and so on caused by sensitive bacteria such as streptococcus and pneumococcus. This product is the only cephalosporin antibiotic with broad antibacterial spectrum, strong antibacterial activity and immunomodulation activity, and little toxic and side effects, which meets the needs of anti-infection in infants.